STOCK TITAN

Director at Co-Diagnostics (NASDAQ: CODX) receives 1,695-share equity grant

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Co-Diagnostics, Inc. director Richard S. Serbin reported equity compensation activity involving restricted stock units. On May 23, 2026, he acquired 1,695 shares of Common Stock at $0.00 per share through a grant and related RSU conversion, rather than an open‑market purchase. After this transaction, he directly holds 10,751 Common shares and 4,000 restricted stock units. The footnotes explain these RSUs were awarded under the company’s 2015 Long Term Incentive Plan with scheduled vesting in six semiannual installments across multiple grant dates.

Positive

  • None.

Negative

  • None.
Insider SERBIN RICHARD S
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,695 $0.00 $0.00
Grant/Award Common Stock 1,695 $0.00 $0.00
Holdings After Transaction: Restricted Stock Unit — 4,000 shares (Direct); Common Stock — 10,751 shares (Direct)
Footnotes (1)
  1. F1. Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2023. Included in 3,667 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2024. Included in 4,167 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2025.
Shares acquired 1,695 shares Common Stock grant and RSU conversion on May 23, 2026
Price per share $0.00 per share Equity compensation, not open-market purchase
Shares held after 10,751 shares Total direct Common Stock holdings following transaction
RSUs exercised 1,695 units Restricted Stock Units converted to Common Stock
RSUs remaining 4,000 units Restricted Stock Units outstanding after the exercise
Underlying RSU shares 5,695 shares Common Stock underlying reported restricted stock units
Restricted Stock Unit financial
"Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Long Term Incentive Plan financial
"pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan"
A long term incentive plan is a company program that awards executives and key employees bonuses—often in stock, options, or cash—only if the business meets multi-year performance goals. It links management pay to company results—like tying a coach’s bonus to a team’s multi-season record—so investors monitor it for how leaders are motivated, potential share dilution, and signals about the company’s long-term priorities.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did CODX director Richard Serbin report?

Director Richard Serbin reported acquiring 1,695 Co-Diagnostics (CODX) common shares via equity compensation. The shares came from a restricted stock unit grant and conversion, not an open-market purchase, and were recorded at a price of $0.00 per share.

How many Co-Diagnostics (CODX) shares does Richard Serbin hold after this Form 4?

Following the reported transactions, Richard Serbin directly holds 10,751 Co-Diagnostics (CODX) common shares. He also has 4,000 restricted stock units outstanding, which may convert into additional common shares as they vest over time under the incentive plan.

Was the CODX insider transaction a market purchase or a compensation grant?

The CODX insider transaction reflects equity compensation, not a market purchase. Richard Serbin received 1,695 common shares at $0.00 per share through a grant and conversion of restricted stock units awarded under the company’s 2015 Long Term Incentive Plan.

What derivative activity involving CODX restricted stock units was reported?

The filing shows an exercise of 1,695 restricted stock units into Co-Diagnostics (CODX) common shares. After this derivative exercise, 4,000 restricted stock units remain outstanding, while 5,695 underlying common shares are tied to these RSU awards under the incentive plan.

How are CODX restricted stock units for Richard Serbin scheduled to vest?

Footnotes state that Serbin’s CODX restricted stock units were granted in 2023, 2024, and 2025 under the 2015 Long Term Incentive Plan. Each grant vests in six equal installments every six months, beginning on November 23 of the year specified for each award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SERBIN RICHARD S

(Last)(First)(Middle)
2401 S. FOOTHILL DRIVE SUITE D

(Street)
SALT LAKE CITY UTAH 84109

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Co-Diagnostics, Inc. [ CODX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/23/2026A1,695(1)A$0.0010,751D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0.0005/23/2026M1,695 (1) (1)Common Stock5,695$0.004,000D
Explanation of Responses:
1. Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2023. Included in 3,667 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2024. Included in 4,167 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2025.
Remarks:
/s/ Richard Serbin05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)